Logo

Triumvira's TAC01-CD19 Receives FDA's Fast Track Designation for R/R Diffuse Large B-Cell Lymphoma

Share this

Triumvira's TAC01-CD19 Receives FDA's Fast Track Designation for R/R Diffuse Large B-Cell Lymphoma

Shots:

  • The US FDA has granted FT designation to Triumvira’s TAC01-CD19 for patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) prior treated with at least two systemic therapies
  • The TAC technology will significantly improve the limitation of existing cell therapies- including the risk of cytokine release syndrome and neurotoxicity- expanding treatment option for the patients
  • TAC01-CD19 is a novel T-cell therapy targeting CD19 with the expected onset of its P-I/II study (TACTIC-19) evaluating patients with CD19-positive B-cell malignancies- including DLBCL by the year-end 2019

Click here to­ read full press release/ article | Ref: Businesswire | Image: BusinessWire


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions